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Abstract
Emerging evidence demonstrates a role of extracellular vesicles (EVs) in a vari-
ety of fundamental physiological and pathological processes ranging from antigen 
presentation to T cell to neurodegenerative diseases. In several types of malignan-
cies, a variety of EVs can be isolated from bodily fluids of cancer patients, and it has 
been reported that the number of circulating EVs seems to be higher than in healthy 
subjects. This increase correlates with poor prognosis. Data obtained from different 
groups clearly point out a role of EVs in the transfer of bioactive molecules such as 
microRNAs and viral oncoproteins in human papillomavirus-induced malignan-
cies of genital and oral tracts. This study summarizes these data in the context of 
relevant literature considering the EVs as carriers of oncogenic signatures in human 
cancer as well as their therapeutic potential in HPV-related tumors.
Keywords: extracellular vesicles, exosomes, microvesicles, human papillomavirus, 
tumorigenesis
1. Introduction
The extracellular vesicles (EVs) are nano- to micro-sized, cell-derived structures 
delimited by a double-layer lipid membrane. Even if the first reports describing 
the existence of “particles” derived from platelets with procoagulant effects and 
the presence in serum of the so-called platelets dust date back to 1946 and 1967, 
respectively [1], exosomes have been considered for a long time just as cell “rubbish” 
materials. Spotlight on EV functions have been turned on in the early 1980s when 
two different groups convincingly demonstrated the role of EVs in the transfer and 
recycling of transferrin receptor in reticulocytes [2, 3]. Since then, a clear role in sev-
eral physiological and pathological processes has been ascribed to EVs. For instance, 
B lymphocyte-derived EVs present antigens and induce antigen-specific response 
in T cells, suggesting a role in adaptive immune responses [4]. EVs have also been 
implicated in almost all the neurodegenerative diseases through the spread of aber-
rant pathogenic peptides/proteins. This is the case of β-amyloid peptides and Tau 
protein in Alzheimer’s disease [5, 6], prion proteins in Creutzfeldt-Jakob disease [7], 
αB-crystallin proteins in both Alzheimer’s disease and multiple sclerosis [8], mutant 
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superoxide dismutase 1 and transactive response DNA-binding Protein 43 (TDP-43) 
in amyotrophic lateral sclerosis [9, 10], and α-synuclein in Parkinson’s disease [11]. 
Furthermore, a variety of EVs can be isolated from bodily fluids of cancer patients in 
several types of hematological and non-hematological malignancies, and it has been 
reported that in these patients, the number of circulating EVs seems to be higher 
than in healthy subjects and correlates with poor prognosis [12].
Human papillomaviruses (HPVs) are responsible for around 33% of all human 
cancers related with infections. To date, more than 200 types of HPVs are classified 
into three main genera (α, β, and γ genus) and several species in the HPV phyloge-
netic tree. High-risk (HR) HPVs are grouped into a subgroup within the α genus. 
HR-HPVs are the etiological agents of cervical carcinomas and anal cancers and 
are involved in other genital tumors as well as in some head and neck tumors [13]. 
Twelve HPV types (i.e., HPV16, HPV18, HPV31, HPV33, HPV35, HPV39, HPV45, 
HPV51, HPV52, HPV56, HPV58, and HPV59) were classified as oncogenic by the 
International Agency for Research on Cancer (IARC), being the HPV16 prevalent 
in HPV-positive malignancies. Among the HR-HPV-associated tumors, the large 
majority is represented by cervical carcinomas (i.e., more than 50,000 over 60,000 
cases per year, data from GLO-BOCAN 2012; http://globocan.iarc.fr). Of note, 
the occurrence of HPV-positive oropharyngeal cancers is incrementing in the last 
decades [14].
Mucosal HR-HPV types belonging to the alpha genus are the only recognized 
to be related to human carcinogenesis by large epidemiological studies. Similar 
studies were performed on the involvement of cutaneous beta HPVs in cancer 
without achieving unequivocal results because these viruses, present in skin 
cancer cells only in small amount, are also present in the healthy skin. However, 
many functional studies on the E6 and E7 of several beta HPVs demonstrated their 
oncogenicity in vivo systems and in transgenic mouse models. These results lead to 
consider HPV5, HPV8, HPV20, HPV36 (β1 species), HPV22, HPV23, HPV38 (β2), 
and HPV49 (β3) as high-risk genotypes. In fact, it is well known that these beta 
HPVs are involved in disseminated infection and in squamous cell carcinoma (SCC) 
of immunocompromised subjects [15, 16]. However, the mechanism of beta HPV 
carcinogenesis is different from that of alpha HPVs; in fact, it has been shown that 
beta HPV types induce tumors in cooperation with other carcinogens such as UV 
ray and chemicals [17].
2. Extracellular vesicles
Previously defined in several ways as oncosomes, prostasomes, ectosomes, and 
microparticles, just to mention a few, EVs are currently named basing on both the 
biogenesis and particles size. According to these criteria, three main classes of EVs 
are identified: apoptotic bodies (ABs), microvesicles (MVs), and exosomes (Exos) 
(Figure 1). Both ABs and MVs are generated by plasma membrane blebbing; ABs 
are produced following cellular shrinking and fragmentation upon induction of 
programmed cell death (PCD) and are the larger vesicles with size ranging between 
500 nm and 1 μm. Conversely, MVs are physiologically released during the cellular 
lifespan and are smaller than ABs (i.e., between 100 and 500 nm up to 1 μm). On the 
other side, Exos are generated by membrane invagination of intracellular corpuscles 
defined multivesicular bodies (MVBs) where they are stored as intraluminal vesicles 
(ILVs). Once MVBs fuse with the plasma membrane, ILVs are secreted in the extra-
cellular space where they are called Exos. Giving the intracellular genesis of these 
EVs, Exos are the smallest class of vesicles being in size between 50 and 150 nm.
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MVs and Exos biogenesis share common elements, particularly the endosomal 
sorting complex required for transport (ESCRT) proteins. Nevertheless, in the case 
of Exos, an ESCRT-dependent and ESCRT-independent machinery exists [18].
Depending on their biogenesis routes, the three classes of EVs carry different 
types of cargos even if all EVs contain lipids, proteins, as well as nucleic acid (i.e., 
RNA and DNA). Furthermore, specificity of EV cargoes depends on cell type and is 
associated with the physiological or pathological condition of the producer cell [19]. 
However, as a general rule, it could be estimated that ABs contain more DNA than 
MVs and Exos due to their release after PCD induction, whereas MVs are enriched 
in mRNA surface proteins and, owing to their synthesis, membranes enriched in 
cholesterol and saturated fatty acid lipids. Among the different classes of EVs, 
Exos are a very peculiar class because of their size and their intracellular synthesis. 
These features are of special interest for researchers because they allow the loading 
of smaller molecules (for instance, microRNAs and other small and long noncod-
ing RNAs rather than mRNAs) and the cargo of proteins able to interact with a 
Figure 1. 
EV biogenesis. Apoptotic bodies and microvesicles are generated by plasma membrane blebbing. Exosomes are 
generated by membrane invagination of intracellular corpuscles defined MVBs where they are stored as ILVs. 
ESCRT, endosomal sorting complexes required for transport; MVBs, multivesicular bodies; ILVs, intraluminal 
vesicles.
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specialized machinery [20]. Nevertheless, at present it is unclear if the elements of 
the machinery used to sort cargo into Exos are dedicated or rather shared with MVs.
As the three classes of EVs have overlapping size, it is not possible to isolate a 
single class of EVs in spite of the different methods utilized, which are based on 
differential centrifugation, density gradients of sucrose or iodixanol, size exclusion 
chromatography, or ultrafiltration. This is especially true in the case of Exos [21]. In 
fact, affinity chromatography-based methods that utilize antibodies or molecules 
able to bind to the phosphatidylserine overexpressed on EV surface [22] are useless 
as well. Indeed, the possible existence of surface proteins or other molecules specifi-
cally expressed by one class of EVs is already matter of debate. The International 
Society for Extracellular Vesicles has just issued some minimal experimental require-
ments for definition of extracellular vesicles and their functions, to allow standard 
assignment of specific biological cargo or functions to a single class of EVs [23, 24].
2.1 Role of EVs in tumorigenesis
EVs serve as shuttle vehicles for intercellular and intratissue communica-
tion by transferring a discrete and complex “data packet” consisting of proteins, 
lipids, and nucleic acids; as a consequence, cancer cells are able to shape tumor 
microenvironment (TME) through the release not only of soluble factors such as 
cytokines, chemokines, and growth factors but also of EVs. As previously reported, 
proliferation, angiogenesis, metastasis, inflammation, limitless replicative poten-
tial, resistance to apoptosis, and suppressive signal are considered hallmarks of 
cancer [25], and a clear role of EVs has been demonstrated in all these processes 
[26]. Surprisingly enough, this “flow of data” is bidirectional, going not only from 
transformed to normal cells (i.e., fibroblast, stromal, and immune cells) but also 
from normal to transformed cells. Exos released from cancer cells, for instance, 
induce neo-angiogenesis and increase vascular permeability, thereby facilitating 
metastasis, through the modulation of endothelial cell activities [27]. Fibroblasts 
are as well a target of tumor-derived EVs that trigger their differentiation into 
cancer-associated fibroblasts with pro-angiogenic and pro-tumorigenic properties 
[28]. Several in vitro tumor models demonstrated the ability of tumor cell-derived 
EVs to transform normal cells. For instance, stromal cells were transformed by Exos 
derived from colorectal cancer cells [29], adipose stem cells were transformed by 
EVs derived from prostate cancer cells [30], and nonmalignant fibroblast murine 
cells isolated from tumor of immunocompromised mice were transformed by 
breast cancer-derived MVs [31]. Further, Exos isolated from sera of breast cancer 
patients induce tumorigenicity of nonmalignant human breast cells when injected 
into immunocompromised mice [32]. However, it is a matter of debate if such a 
phenomenon occurs also during tumorigenesis. Tumor EV cargo can be represented 
by mutated oncoproteins [33, 34], mRNA codifying for fusion transcripts [35], 
oncogenic long noncoding RNAs (lncRNAs) [36], and miRNAs associated with 
chemotherapy resistance [37].
Conditions associated with tumor growth, like hypoxia, influence both quanti-
tatively and qualitatively the EVs released from cancer cells. When co-injected into 
SCID mice with human glioblastoma cell line, hypoxic EVs increase both tumor 
growth and angiogenesis [38], whereas breast cancer cell lines preincubated with 
hypoxic EVs and injected into mice develop more metastases than the same cells 
preincubated with normoxic EVs [39].
When cancer cells leave the site of primary growth, they travel through the blood 
stream acquiring the ability to colonize other sites, thereby generating metastases. It 
is now evident that these circulating tumor cells (CTCs) are not able to colonize all 
tissues but only specific sites called pre-metastatic niches, where a favorable TME 
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has been pre-generated [40]. Due to their peculiar nature, EVs are one of the tools 
most used by tumors to create pre-metastatic niches. Interestingly, EVs derived from 
different types of tumor show different tissue tropism. Melanoma-derived EVs target 
the lung, liver, bone, and brain, whereas colorectal cancer-derived EVs form predomi-
nantly liver metastasis. EVs derived from most tumors show a tropism for the bone 
marrow, thereby generating pre-metastatic bone marrow niches [41, 42]. Although 
the surface receptors determining the specificity of EVs tropism are unknown to 
date, the resulting effect is a reprogramming of local target cells that produce soluble 
factors and extracellular matrix remodeling, necessary for the settlement of CTCs. 
In other cases, metastasis is dependent not on EVs derived from primary tumor but 
on EVs released by cells of the target site. For instance, it has been demonstrated that 
in the brain, but not in other tissues, breast cancer loses tumor suppressor PTEN; 
this effect is mediated by miR-19a contained in astrocyte-derived Exos [43]. Aging 
[44] and infection [45] are as well conditions able to create a favorable niche, called 
in that case active metastatic niche, independent of EVs derived from primary tumor 
but dependent on EVs produced in loco. This influence of EVs derived from normal 
cells on transformed ones could even have an opposite effect. Indeed, in some cases, 
EVs from normal tissues generate an unfavorable field for CTCs, thus inducing the 
so-called cancer cell dormancy. This is the case of bone marrow mesenchymal stem 
cell-derived Exos which induce dormancy of breast cancer cells through a miR-
23b-mediated mechanism [46].
Another important feature of tumor-derived EVs is their immunomodulatory 
ability to subvert or evade immune recognition. To accomplish this task, EVs interact 
with surface immunoreceptors or are internalized within immune cells, thereby 
hindering activation and polarization into effector or cytotoxic T lymphocytes. 
Ligands of death receptors, as TNF-R1 and Fas, are engaged on CTL surface by 
ligands expressed on EVs, leading to the induction of apoptosis in these cells [47, 48]. 
Tumor-derived EVs also play a role in both T- and myeloid cell differentiation by 
inducing the generation of regulatory T cells and myeloid-derived suppressor cells, 
respectively [47, 49]. Finally, NK cells are also targets of tumor-derived EVs [50]. 
Immunomodulatory activity of tumor-derived EVs on NK cells is also improved by 
hypoxic conditions through a TGFβ and miR-23a mechanism [51].
3. HPV-induced tumorigenesis
The infection by HPVs that is very frequent in sexually active women can have a 
driving role in the improvement of tumor injuries of the uterine cervix. The uterine 
cervical carcinoma (CC) is the third most frequent tumor in women, and the high-
risk (HR) HPV is found in about the totality of this tumor [52].
HPV can reach the deep layers of the epithelium through cervical microwounds 
and enter immature, multiplying cells, where the viral DNA is kept up as an epi-
some and replicates through the host cell genome. As a consequence, the infected 
immature cervical cells remain in a proliferative state, obstructing their terminal 
differentiation [53].
During the HPV DNA replication, the HPV early genes, including those coding 
for the E6 or E7 proteins, are transcribed, but their expression is kept low by the 
HPV-E2 protein. However, E6 and E7 are produced at levels acceptable to impair 
the factors that regulate the growth and the differentiation of the host cell. HPV-E7 
binds to and inactivates the retinoblastoma tumor suppressor protein (pRb), ham-
pering infected cells to leave the cell cycle and differentiate. Meanwhile, HPV-E6 
guides the host cell tumor suppressor protein p53 toward degradation through the 
proteasome of the cell with the consequence that E6 upregulates the intracellular 
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levels of the anti-apoptosis Bcl-2 protein, normally blocked by p53, and triggers the 
activity of telomerase that represses replicative senescence by stabilizing the length 
of the chromosomes end. Overall, the E6 and E7 activities block the apoptosis due to 
p53 in the HPV-infected cells, necessary to control cellular proliferation [54].
In around 80% of the cases, HPV-induced cell proliferation stays at subclinical 
level, developing cervical epithelium thickness or causing benign flat warts. In the 
remaining cases, HPV-E6 or HPV-E7 stimulates the growth rate of immature cervi-
cal basal and parabasal epithelial cells and their transfer to the superficial layer. This 
prompts the improvement of squamous intraepithelial injuries.
Usually, an immune reaction to HPV happens in few months after infection, 
with the consequence of viral clearance. From that point forward, the p53 and pRb 
function is restored in the basal and parabasal layers, and epithelial cell growth and 
differentiation return to normal. This event usually occurs in infections with low-
risk HPV types, e.g., HPV6 or HPV11, whose DNA remains episomal.
On the other hand, persistent infection with HR-HPV, including HPV16 and 
HPV18, can be followed by the integration of viral DNA into the host cell genome. 
HPVs are kept up as episomes in precancerous lesions, while in some high-grade 
lesions, genomes can integrate into the host chromosome [55]. While there is no 
accord about the exact role of viral integration in HPV-induced cancer progression, 
it appears that the deregulation of E6 and E7 expression during viral integration 
contributes to the development of high-grade lesions. In this particular circum-
stance, cell key mitotic checkpoints are impeded, bringing to genomic instability, 
accumulation of mutations, and aneuploidy in infected cells. Subsequently, the 
entire cervical epithelium is replaced by poorly differentiated cells showing anoma-
lous nuclei and atypical mitoses. The E6 and E7 proteins support this process by 
their ability to induce genetic instability of the host cell DNA and by deregulating 
cell factors related with epigenetic reprogramming. Recently, a number of studies 
have enhanced the information of phenotypic effects induced by the HPV-E6 and 
HPV-E7 oncoproteins. It was demonstrated that oncogenic HPVs contribute to 
all the main phenotypic changes of cancer cells defined as “hallmarks of cancer” 
[25], from sustained proliferative signaling, sidestepping growth suppressors, and 
activating tissue invasion and metastasis to empowering replicative immortality, 
initiating inflammation and angiogenesis, and repressing cell death.
In any case, the expression of the HPV-E6 and HPV-E7 oncogenes is necessary but 
not sufficient for HPV-induced carcinogenesis. This statement is supported by the 
proof that only few women infected with an oncogenic HPV type will develop cervical 
cancer. Likewise, this process requires a very long time after infection and is character-
ized by the presence of premalignant precursor lesions with expanding grades of cell 
dysplasia (cervical intraepithelial neoplasias, CIN, stages 1–3), which either spontane-
ously relapse or, in the minority of cases, progress to invasive cancer [56].
The risk to develop invasive CC is increased by the use of oral contraceptives, 
smoking, early sexual practice, different sexual partners, and coinfections.
In addition, HPV utilizes several mechanisms to contrast the host immune response, 
for example, the suppression of innate immunity, inhibition of T-cell effector function, 
frequent loss of human leukocyte antigen (HLA) expression, and genetics events, all of 
which can lead to immune evasion. If the immune system fails to clear persistent HPV 
infections, after several decades, progression to cervical cancer appears [57].
It is important to underline that the extra alterations required for HPV tumor 
progression are not restricted to epigenetic changes inside the cell but also with 
the crosstalk with external cofactors. For example, the microbiome at individual 
body sites can affect tumor development [58]. Surprisingly, during progression of 
HPV-positive lesions to cervical tumor, microorganisms resident in cervicovaginal 
microbiome increase, and Lactobacillus spp. diminish [59].
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Moreover, different investigations have been performed to analyze the 
microRNA (miRNA) expression profile in cervical cancer, and important relation-
ships have been found between miRNA patterns and cervical tumor.
MicroRNAs are short RNAs that control the transcriptome and proteome at 
posttranscriptional level. To deeply understand the role of miRNAs in cervical can-
cer progression, meta-analysis and gene set enrichment analysis have been utilized 
to examine studies already published on miRNAs in cervical cancer [60].
It has been demonstrated that some of the dysregulated miRNAs are connected 
with specific phases of cervical growth development. To study the impact of miR-
NAs on the pathogenesis of cervical cancer, a miRNA-mRNA interaction network 
on chosen pathways was created by incorporating viral oncoproteins, dysregulated 
miRNAs, and their predicted/validated targets. The study has demonstrated that 
miRNAs deregulated at the different stages of cervical cancer are functionally 
associated with several key cancer-related pathways, for example, cell cycle, p53, 
and Wnt signaling pathways. These dysregulated miRNAs may have an important 
role in tumor development. Some of the stage-specific miRNAs can also be utilized 
as biomarkers for tumor characterization and checking of cancer development.
It has been demonstrated that miRNAs are discharged into the extracellular 
space or in the circulation framework in either microvesicles or exosomes [5]. In 
particular, exosomes have the ability to convey their load to recipient cells through 
receptor-mediated interactions. Unexpectedly, some studies have shown that some 
miRNAs are not transported by exosomes, but rather can be fairly recognized in a 
free soluble form, protected by RNA-binding proteins [61, 62]. The type of delivery 
of circulating miRNAs could depend on the type of tissue damage, suggesting 
an alternative role for every kind of transport and demonstrating that different 
types of cells, for instance, the endothelial cells, could contribute to the delivery of 
circulating inflamma-miRNAs.
3.1 Role of EVs in HPV-induced tumorigenesis
In spite of the fact that a connection between tumorigenesis and synthesis/
release/function of EVs had been shown before, the role of EVs in the pathogenesis 
of HPV-induced malignancies began to be observed just lately (Table 1). The first 
confirmation of the involvement of EVs in the pathogenesis of HPV tumorigenesis 
dates back to 2009, when the presence of extracellular Survivin in HPV-18 posi-
tive cells HeLa was suggested [63]. Cell medium containing Survivin shows anti-
apoptotic, proliferative, and pro-metastatic potential with respect to inactive T34A 
mutant [63]. After 2 years, the same researchers showed that extracellular Survivin 
was integrated in Exos and that proton irradiation caused synthesis and release 
of these Exos [64]. These Survivin-positive Exos were then investigated for their 
protein cargo content by examining the stress-induced proteins. Therefore, the 
presence of other inhibitor of apoptosis proteins (IAPs) as XIAP, c-IAP1, c_IAP2, 
and Livin/ML-IAP was shown [65, 66]. The presence of IAPs relied upon HPV 
oncoproteins, since Exos obtained from E6- and E7-silenced HeLa cells showed a 
decrease in the expression of these inhibitors; surprisingly, E6-/E7-silenced HeLa 
secreted more Exos than control cells [66]. The cargo content of HeLa-derived, 
Survivin-positive Exos was additionally described at the level of miRNAs [67]. 
The researchers demonstrated that 52 miRNAs were deregulated and the expres-
sion of 23 out of these was influenced by E6/E7 silencing. Most of the upregulated 
miRNAs play a pro-proliferative, anti-apoptotic, and anti-senescent role. The 
downregulated ones play instead opposite functions. Very important is also the 
fact that miRNA content of Exos showed a comparative but not superimposable 
profile of expression, since 11 out of 46 miRNAs found in Exos are not deregulated 
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in cells, proposing the presence of specific mechanisms for incorporation of these 
miRNAs into Exos. The analysis was also performed in the HPV-16-positive cell 
line SiHa with superimposable results, proposing that HPV deregulation of miRNA 
References Type 
of EVs
EV source Purification 
method
Cargo 
type
Cargo 
hallmark
Aromseree 
et al.
[77] Exos EBV-infected 
LCLs
Differential 
centrifugation
Viral 
mRNAs
EBER1
EBER2
Chiantore 
et al.
[68] Exos E6-/
E7-transduced 
primary human 
keratinocytes
Differential 
centrifugation
miRNAs miR-222
Carolis 
et al.
[82] EVs Sera Differential 
centrifugation
DNA Circular 
HPV DNA
Gaiffe et al. [75] ABs HeLa CaSki — DNA E6 and E7 
DNA
Gezer et al. [70] Exos HeLa Differential 
centrifugation 
plus filtration
lncRNAs lincRNAp21
CCND1-
ncRNA 
HOTAIR, 
TUG1
GAS5, 
MALAT1
Harden 
et al.
[69] Exo-
EVs
Primary human 
keratinocytes
Total exosome
isolation 
reagent
miRNAs miRNAs 
connected 
to apoptosis, 
necrosis, 
and cell 
viability
Hermetet 
et al.
[76] ABs HeLa
CaSki
— — —
Honegger 
et al.
[66] MVs HeLa Differential 
centrifugation
Proteins Survivin, 
XIAP,
c-IAP1, 
Livin
Honegger 
et al.
[67] Exos HeLa Differential 
centrifugation
miRNAs Several 
miRNAs 
deregulated
Kannan 
et al.
[81] Exos Sera
UM-SCC-104
Commercial 
kits
Proteins HPV16-E7
MUC16
SIRPA
Khan et al. [63] Exos HeLa S Differential 
centrifugation
Proteins Survivin
Liu et al. [79] Exos Cervicovaginal 
lavages
Differential 
centrifugation
miRNAs miR-21
miR-146a
Rana et al. [72] EVs Primary human 
keratinocytes
Differential 
centrifugation
Proteins IL-36γ
Valenzuela 
et al.
[65] Exos HeLa ExoQuick Kit Proteins Survivin, 
c-IAP1,
c-IAP2, 
XIAP
Zhang 
et al.
[80] Exos Cervicovaginal 
lavages
Differential 
centrifugation
lncRNAs HOTAIR, 
MALAT1, 
MEG3
Table 1. 
EV type and cargo in HPV+ cells/specimens.
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expression is not genotype-specific [67]. The study of miRNAs performed in Exos 
obtained from primary keratinocytes transduced with E6 and E7 from HPV-16 
or HPV-38 confirmed the results obtained in the cell lines by Honegger et al. and 
showed in these vesicles the presence of mRNA coding for E6 and E7 and the capac-
ity of Exos to transfer these mRNAs to non-transduced keratinocytes [68]. Focusing 
on a panel of some tumor-related miRNAs, Harden and Muller acquired comparable 
expression profiles between cell- and Exos-related miRNAs [69]. Other researchers 
demonstrated the presence of long noncoding RNAs (lncRNAs) into HeLa-derived 
Exos checking the presence of lincRNA-p21, CCNDA1-ncRNA, HOTAIR, TUG1, 
and GAS5 [70]. Significantly, lincRNA-p21, the most overexpressed lncRNA in 
Exos compared to parental cells, is a repressor of p53-dependent transcriptional 
responses [71] suggesting that his horizontal transfer may influence gene expres-
sion in acceptor cells.
EVs derived from HPV-positive cells are likewise able to horizontally transfer 
cytokines and mRNA thereof, consequently assuming an immunomodulatory role 
in the cancer microenvironment. Rana et al. showed the presence of proinflamma-
tory cytokine IL-36γ into EVs isolated from Poly(I:C)-treated keratinocytes [72]. 
Since it has been reported that HPV-16 suppressed the Poly(I:C)-induced expres-
sion of several proinflammatory genes [73], it is conceivable to think that IL-36γ 
expression in EVs is suppressed by HPVs. According to this anti-inflammatory 
function, the expression of many proinflammatory cyto- and chemokine mRNAs is 
deregulated in E6-/E7-transduced keratinocytes, and as in the case of miRNAs, this 
profile is sufficiently conserved in EVs with a statistically significant reduction of 
IL-1α, IL-1β, CCL27, CXCL1, CXCL3, and angiogenin mRNAs [74].
Different classes of EVs have been also related to HPV-induced tumorigenesis. 
It has been shown that ABs transfer viral DNA to nonprofessional phagocytic cells 
[75]. Specifically, these researchers showed that human primary fibroblasts could 
internalized ABs derived from apoptotic Hela or CaSki (HPV16+) cells and follow-
ing this internalization showed a transformed phenotype (i.e., development in soft 
agar, aneuploidy, diminished expression of p53 and p21). This internalization of 
apoptotic cells, made by both professional and non-professional phagocytic cells 
and called efferocytosis, happens in a time- and stage-dependent manner since 
only late apoptotic fragments were able to be taken up by normal fibroblasts; on 
the contrary, professional phagocytic cells internalize with high effectiveness and 
degrade both early and late ABs without indications of transformation [76].
EVs, and especially Exos, may be involved in the viral crosstalk, as in the case 
of coinfection with HPV and Epstein–Barr virus (EBV). It has been reported 
that Exos from EBV-positive lymphoblastoid cell lines and containing EBV small 
noncoding RNAs, called EBERs, are delivered to HPV-positive keratinocytes [77]. 
In EBV-positive cells, EBERs can affect innate immunity and cell proliferation [78], 
but in the case of their horizontal transfer to HPV-positive keratinocytes, their role 
remains elusive [77].
The delivery potentiality of EVs, in terms of cargo content and possibility to 
recover them from virtually all the bodily fluids, makes them an ideal diagnostic 
and prognostic tool to monitor tumor onset and progression as well as therapy 
effectiveness while avoiding invasive procedures. The liquid biopsy approach has 
been recently applied also in HPV-positive carcinomas. The first attempt to study 
EVs in specimens collected from HPV-positive cancer dates back to 2014 [79] when 
it was demonstrated that exosomal miR-21 is overexpressed in HPV-positive normal 
specimens and even more in HPV-positive cervical cancer specimens compared 
to normal HPV-negative ones. In addition, Exos from cervicovaginal lavages of 
both HPV-positive normal and cancer patients contain more HOTAIR, MALAT1, 
and MEG3 lncRNAs [80]. Moreover, in HPV-16-associated oropharyngeal cancer 
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(HPVOPC), serum collected from patients contains Exos expressing key altered 
proteins, namely, mucin-16 (MUC-16) and signal regulatory protein α (SIRPA) 
as well as E7 oncoprotein [81]. Similarly, Exos derived from a HPVOPC cell line 
displayed the ability to induce epithelial-mesenchymal transition (EMT) and 
invasiveness of two human mammary epithelial cell lines [81]. Finally, the presence 
of EVs containing HPV DNA was analyzed in the serum of patients with breast 
cancer. The authors found two out of eight HPV DNA-positive specimens among 
patients with ductal carcinoma in situ with a complete correspondence between 
tissue and serum-derived EV specimens and one out of fourteen HPV DNA-positive 
specimens among benign breast disease-affected women [82].
4. Engineered exosomes in immunotherapy of HPV-related tumors
Exosomes, in virtue of the properties of stability, biocompatibility, and low 
immunogenicity and of the possibility to be loaded with a cargo, are increasingly 
explored as therapeutic delivery agents for drugs and small molecules in a number 
of pathological conditions. Importantly, exosomes hold good stability while pre-
serving the activity of the molecules shipped, which are fundamental characteris-
tics for delivery, while the outstanding hallmark concerns safety, being a cell-free 
and very controllable system. In the recent past, exosomes have been investigated 
for the delivery of siRNAs, miRNAs, shRNAs, and anti-inflammatory/anticancer 
agents as curcumin and doxorubicin and paclitaxel.
Working either through the parental cells or the environmental milieu, exosomes 
can be tailored to target definite diseases, e.g., by expressing specific surface ligands 
and receptors and loading them with therapeutic agents. In alternative to the manipu-
lation of exosomes through the biogenesis in the parental cell line, exosomes can 
be purified and then modified for incorporating therapeutic molecules. Exosomes 
delivered by systemic route preferentially accumulate in the liver, spleen, and kid-
neys, but by scaling the dosage and changing the route of administration, it is possible 
to affect biodistribution. As the exosome tropism is affected by the donor cell type 
which determines the membrane composition, attention must be paid to the fact that 
tumor exosome content is enriched in molecules that can promote tumorigenesis.
A number of applications of therapeutic exosomes in pathologic conditions such 
as diabetes, cancer, and cardiovascular and neurological diseases are under investi-
gation, with some of them in phase I and one (advanced non-small lung cancer) in 
phase II clinical trial. For their part, HPV tumors represent per se targetable lesions 
because of their confined localization and lend themselves to being attacked by an 
exosome-based immunotherapeutic approach that can be either active or passive.
The first studies utilizing exosomes in immunotherapy are dated 20 years ago 
and used B-cell-derived exosomes to induce MHC-restricted T-cell responses [4]. In 
the next studies, exosomes were proposed as tumor vaccines for a number of can-
cers such as melanoma, glioma, hepatocellular carcinoma, and renal cell carcinoma 
[83–89], due to their capability to deliver antigens from professional APCs such as 
DCs to other APCs.
Cervical cancer immunotherapy using dendritic cells pulsed with exosomes 
derived from HeLa cells was recently proposed. Monocyte-derived dendritic 
cells from cervical cancer patients were matured in vitro to DCs and pulsed with 
exosomes purified from HeLa culture medium with an opportune protocol. These 
HeLa-exo pulsed DCs in co-culture experiments with autologous lymphocytes 
showed the ability to stimulate a strong T-cell activation and a CTL-specific cyto-
toxic response [90]. In a mouse animal model, HPV-specific cytotoxic activity use-
ful in cervical cancer immunotherapy was also demonstrated using exosomes [91].
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Proteins localized into the membrane compartment generating exosomes can 
be used as carriers for delivering other proteins into the exosomes: this is the case 
of the HIV-1 Nef protein. A Nef mutant (Nefmut) was generated from a natural 
defective HIV-1 expressing a Nef variant with the property to accumulate in 
abnormal quantities in the raft membranes and then in exosomes, compared to the 
wild-type protein [92]. This 27 kDa Nefmut, both myristylated and palmitoylated, 
was appropriately engineered to work as a carrier for other proteins long up to 630 
amino acids, once fused to its COOH terminus. It has been demonstrated that the 
fusion products can be incorporated not only into genome-free viral particles of 
HIV-1, working as a vaccine [93], but also into exosomes of cells transfected with 
the corresponding DNA constructs.
To develop a therapeutic vaccine for the cure of HPV16-related tumors, the 
HPV16-E7 and HPV16-E6 tumor-specific antigens were fused to Nefmut and 
expressed in HEK 293 T cells into the exosomes, anchored to the membrane by 
Nefmut. Mice harboring subcutaneous HPV16-specific tumors, when immunized 
with recombinant Nefmut-E7 or Nefmut-E6 exosomes, developed a strong specific 
cell-mediated immune response, which were able to block the growth and reduce 
the burden of the tumors generated by injection of TC-1 tumor cells [94, 95]. The 
production of recombinant exosomes and their purification for therapeutic vaccine 
development are nevertheless multistep procedures difficult to scale-up. For this 
reason, the Nefmut expression in exosomes was also pursued and obtained from 
Nefmut-E7 or NefmutE6 DNA plasmids in vitro and in vivo. The results allowed to 
develop an upgraded HPV16 therapeutic vaccine based on the DNA inoculation of 
Nefmut-E7 and Nefmut-E6 plasmids [96].
The peculiarity of the Nef-fused antigens is to be cross presented to the T cells 
once they reach the dendritic cells in form of exosomes, forming the platform for 
the genesis of CTL vaccines [97].
Nefmut is also being investigated for the delivery of therapeutic intracellular 
antibodies against the HPV-E6 and HPV-E7 oncoproteins. Anti-HPV16-E6 and anti-
HPV16-E7 antibodies in single-chain format were previously shown to exert anti-
proliferative activity in HPV-positive cells in vitro and therapeutic efficacy against 
HPV-positive tumors in animal models [98]. Preliminary experiments show that 
exosomes purified from cells transfected with plasmids expressing the Nefmut-anti-
16E7 scFv fusion protein contain an antibody in an active conformation able to bind 
to the target E7 (Accardi et al., unpublished), exactly as what occurs for the scFv 
delivered as DNA or protein [98, 99]. In view of the translational application of 
these antibodies in the clinic for the treatment of preneoplastic HPV-related lesions 
localized in the anogenital area or even in the oropharynx, exosomes can represent 
a safe and easy delivery tool. These results represent an incentive to continue the 
studies, albeit with the awareness of the limits of this strategy, mainly consisting of 
the lack of reliable standardized methods for the control of exosome contents and 
purification and of the limited number of exosomes that can be produced.
5. Conclusions
Our knowledge of the EV biology and role, mainly with respect to virus infec-
tion, is still in its infancy. Studies have demonstrated that the delivery of viral 
and cell factors by EVs empowers the control of neighboring unaffected cells. 
Communication by MVs enables the virus to interact with, and control, cell 
microenvironment. Various reports proposed that virus infections use the cell 
vesiculation pathways for virus maturation, immune evasion, and intercellular 
correspondence. In addition, there is expanding proof of tumorigenic properties 
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of Exos and MVs derived from cancer cells, depending on either a direct effect of 
oncogenes transferred to beneficiary cells or an indirect effect of modification of 
the TME. Importantly, in virus-induced cancer cells, the Exos cargo is different 
from that of the non-infected cells. These EVs seem to be enriched with viral or cell 
oncogenic factors as oncoproteins and oncomiRs. Thus, viral-modified Exos may 
function to horizontally transfer oncogenic molecules among neighboring cells, but 
they are also armed to manipulate the TME by favoring angiogenesis and inflamma-
tion or exerting immunosuppressive effects.
6. Executive summary
• Extracellular vesicles are mediators of intercellular and intra- and intertissue sig-
nals that transfer discrete cargo composed by nucleic acids, proteins, and lipids.
• Extracellular vesicles are involved in both physiological and pathological 
processes.
• Tumors exploit extracellular vesicles to reshape the microenvironment, repro-
gram normal neighboring cells, evade cell-mediated immune responses, and 
prepare pre-metastatic niches.
• Human papillomavirus infection has a deep impact on extracellular vesicle cargo 
in terms of protein expression, mRNA, lncRNAs, and miRNA content as well as 
viral DNA transfer via apoptotic bodies.
• Mediators transferred by extracellular vesicles released from HPV-positive cells 
are involved in proliferative, anti-apoptotic, and anti-senescence pathways.
• Extracellular vesicles released from HPV-positive cells contain mRNAs for cyto-
kines and chemokines suggesting a role of these mediators in the reshape of 
tumor microenvironment.
• Due to their stability and low immunogenicity, extracellular vesicles represent 
an ideal tool for the delivery of chemotherapeutic drugs to tumor cells as well as 
for the stimulation of antitumoral immune responses.
• In the next few years, tumor-specific and tumor-associated extracellular vesicles 
will represent a versatile diagnostic and/or prognostic marker to be detected in 
blood samples in the liquid biopsy.
7. Future perspective
EVs may represent an innovative tool for the diagnosis, the prognosis, and the 
follow-up of malignancies as well as for the delivery of anticancer drugs. The ability 
to vehiculate and protect their cargo from lytic enzymes as well as immune effec-
tor mechanisms makes EVs an ideal support for the so-called liquid biopsy and for 
the next-generation cancer therapy. Indeed, valuable markers as cancer-associated 
DNAs, mRNAs, miRNAs, and other lncRNAs are protected from the activity of 
nucleases present in the plasma. Tumor-specific or tumor-associated antigens could 
be more efficiently presented to immune cells or transferred to antigen-presenting 
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cells using EVs rather than artificially synthesized liposomes. These scenarios are 
predictable for all the malignancies, especially those associated with oncoviruses 
where tumor-specific antigens are well expressed (i.e., E6 and E7 in the case of 
HR-HPV). Nevertheless, little is known about the biogenesis and release as well 
as the cargo content of EVs especially in terms of expression of specific tumor- or 
tissue-associated EV antigens. In the next few years, “benchtop” research will be 
focused on these aspects of EV biology, thereby leading to “bedside” diagnostic and 
clinical application of EVs.
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